A post hoc analysis of data collected in one of the pivotal phase 3 trials of dupilumab (Liberty Asthma Quest) [80] compared subjects meeting serologic criteria for ABPA (total IgE > 1000 IU/mL, Aspergillus-specific IgE > 0.35 IU/mL, eosinophils > 500) receiving dupilumab (n = 18) to those receiving a placebo (n = 12) [82]. Here, IGHE is linked to asthma.